Table 2.
Patients with poor adherence to medication.
| Case | Drug | Adherence rate (%) |
Age (years) |
Gender | Genotype | HBeAg | HBV DNA (log IU/mL) |
ALT (IU/L) |
APRI | HBeAg- seronegative |
HBV DNA negativity |
VT | Duration of treatment before VT (months) |
Resistance mutations |
Treatment after VT | Clinical outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ETV | 50 | 55 | F | B | - | 3.8 | 16 | 0.33 | N.A. | + | + | 6 | - | ETV | good |
| 2 | ETV | 75 | 49 | M | C | + | 7.3 | 107 | 1.60 | + | + | + | 28 | + | LAM+ADV | good |
| 3 | ETV | 85 | 38 | M | C | + | 6.9 | 59 | 2.80 | - | + | + | 29 | N.D. | ETV | good |
| 4 | ETV | 80 | 39 | M | C | + | 5.8 | 51 | 0.63 | + | + | - | N.A. | N.A. | ETV | good |
| 5 | ETV | 85 | 37 | F | C | + | 6.9 | 160 | 2.25 | + | + | - | N.A. | N.A. | ETV | good |
| 6 | ETV | 85 | 66 | M | N.D. | + | 7.7 | 68 | 0.95 | - | - | - | N.A. | N.A. | ETV | good |
| 7 | ETV | 85 | 38 | M | C | + | 6.5 | 478 | 7.94 | - | + | - | N.A. | N.A. | ETV | good |
| 8 | LAM | 50 | 47 | F | C | + | 6.5 | 455 | 2.54 | + | + | + | 45 | - | LAM | good |
| 9 | LAM | 80 | 36 | M | C | + | 7.0 | 110 | 4.25 | + | + | + | 41 | + | LAM+ADV | good |
| 10 | LAM | 85 | 23 | M | C | + | >7.6 | 161 | 3.53 | - | + | + | 11 | - | cessation | flare |
| 11 | LAM | 85 | 32 | M | C | + | >7.6 | 343 | 1.30 | + | + | - | N.A. | N.A. | LAM | good |
| 12 | LAM | 85 | 54 | F | C | - | 4.1 | 196 | 2.68 | N.A. | + | - | N.A. | N.A. | LAM | good |
| 13 | LAM | 85 | 36 | M | C | + | 6.7 | 1576 | 15.78 | + | + | - | N.A. | N.A. | LAM | good |
Cases 2 and 3 had already been included in a previous report.10 HBeAg, hepatitis B e antigen; HBV DNA, hepatitis B virus deoxyribonucleic acid, ALT, alanine aminotransferase; APRI, aspartate aminotransferase platelet ratio index; VT, viral breakthrough; ETV, entecavir; LAM, lamivudine; ADV, adefovir; F, female; M, male; N.D., not determined; N.A., not available; HBeAg-seronegative, conversion to HBeAg-seronegative after administration of a nucleoside analogue; HBV DNA negativity, achieving HBV DNA negativity after administration of a nucleoside analogue; flare, fluctuating ALT after treatment after VT.